Aktis Oncology: T. Rowe Price reports 6.2% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Aktis Oncology, Inc. (AKTS) shares were the subject of an ownership report by T. Rowe Price Investment Management, Inc., which reported beneficial ownership of 3,333,026 shares, or 6.2% of the class, as of September 30, 2026. It reported sole voting and sole dispositive power over 3,333,026 shares, with no shared voting or dispositive power. The investment manager expressly denied that the report should be construed as an admission that it is the beneficial owner of the securities.
Key Figures
Key Terms
beneficial owner financial
sole voting power financial
sole dispositive power financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.